Democratizing Cell Therapies
Wednesday, March 30, 2022
4:00 PM-5:30 PM
BIOMED Seminar
CLICK HERE TO ATTEND
Title:
Democratizing Cell Therapies
Speaker:
Jill Carton, PhD
Senior Director
CAR Engineering and Protein Sciences
Century Therapeutic
Details:
Century Therapeutics is developing genetically engineered, inducible pluripotent stem cell or IPSC-derived iNK and iT cell product candidates for hematologic and solid tumor malignancies that have the potential to overcome the limitations of first-generation cell therapies. Autologous chimeric antigen receptor T cells (CAR-Ts) have shown proof of concept and valuable clinical efficacy, but face several inherent limitations, including the dysfunction of the patients own T-cells, patient-to-patient variability resulting in variable efficacy and toxicities, and a limited number of tolerated genetic manipulations, which limit their therapeutic potential.
Century Therapeutics is leveraging its iPSC platform to develop allogeneic cell therapies that go beyond what is achievable by autologous products and donor derived allogeneic cell therapies. The presentation will review the core technologies and science behind our platform and the exciting novel therapeutics we are advancing.
Biosketch:
Jill Carton, PhD, is a Senior Director of CAR Engineering and Protein Sciences at Century Therapeutic in Philadelphia, PA. Jill and her team discover tumor antigen binders and engineer the therapeutic chimeric antigen receptors (CARs) that are incorporated into Century Therapeutics allogeneic cell therapies.
Prior to joining Century Therapeutics in 2019, Jill worked at Janssen Pharmaceuticals in the Biologics Research Department for over 20 years. During that time, she progressed more than 8 biologics drugs through the discovery department and into the clinic. Three of the drugs are currently marketed biologics. Jill received her MS and PhD degrees from Fordham University, Bronx NY, and her BS from Fairfield University, in Fairfield, CT.
Contact Information
Lisa Williams
ltw22@drexel.edu